GSK1059865_LCMS_28082_MedChemExpress
鬼针草提取物中多糖含量及分子量的测定
ｑｑ ｃｏｍ
通讯作者:何 琳ꎬ女(１９８０ － ) ꎮ 学历:硕士ꎮ 职称:高级实验师ꎮ 研
究方向:制剂新剂型与新技术ꎮ Ｅ￣ｍａｉｌ:ｈｅｌｉｎ７２１＠ １６３ ｃｏｍ
溶解后置于 １００ｍＬ 容量瓶中ꎬ以 ８０％ 浓硫酸定容ꎬ摇匀ꎬ即得
一起置于沸水浴中ꎬ自水沸腾开始计时煮沸 １０ｍｉｎꎬ取出放入
冰水浴中冷却至室温后取出ꎮ 按照紫外￣可见分光光度法ꎬ在
波长 ４００ ~ ８００ｎｍ 范围内进行光谱扫描ꎮ 结果表明 Ｄ￣无水葡
萄糖标准品溶液和鬼针草多糖供试品溶液在波长 ６２４ｎｍ 处
有最大吸收ꎬ故选择测定波长为 ６２４ｎｍꎮ
基金项目:广东省化妆品工程技术研究中心开放基金资助项目( 粤科
２０ ０５ｍｇꎬ加入蒸馏水溶解后置于 １００ｍＬ 容量瓶中ꎬ以蒸馏水
定容ꎬ摇匀ꎮ 即得浓度为 ０ ２００５ｍｇｍＬ － １ 的葡萄糖标准品溶
液ꎮ
仪器有限公司) ꎻＳＡＲＴＯＲＩＵＳ ＣＰ２２５Ｄ 十万分之一电子天平
２ ２ １ ２ 供试品溶液:精密称取 ０ ０５２０ｇ 鬼针草粗多糖ꎬ加
浓度为 ０ １０４０ｍｇｍＬ － １ 的鬼针草多糖供试品溶液ꎮ
设备厂) ꎮ
２ ２ １ ３ 蒽酮￣硫酸显色剂:称取 ０ ２ｇ 蒽酮ꎬ加 ８０％ 浓硫酸
品( 中国食品药品检定研究院ꎬ批号 １１０８３３￣２０１７０７) ꎻ氯仿、
浓度为 ２ ０ｍｇｍＬ － １ 的蒽酮￣硫酸显色剂ꎬ需现配现用ꎮ
中图分类号:Ｒ２８４ 文献标识码:Ａ 文章编号:１００６￣３７６５(２０１９) ￣１２￣０２１５１￣００６０￣０３
鬼针草为菊科( Ｃｏｍｐｏｓｉｔａｅ) 鬼针草属( Ｂｉｄｅｎｓ Ｌ ) 一年生
高效液相色谱法测定健胃消食片中橙皮苷的含量
高效液相色谱法测定健胃消食片中橙皮苷的含量摘要】目的：采用高效液相色谱法测定健胃消食片中橙皮苷的含量。
方法：采用高效液相色谱方法，色谱柱：VP-ODS柱（4.6mm*250mm,5um）,柱温30摄氏度，流动相：甲醇：0.5%冰醋酸溶液（40:60），检测波长：285nm，流速1.0ml/min，进样量20ul。
结果：当进样量为0.05～12微克时，进样量与峰面积有良好的线性关系，仪器具有良好精密度时RSD=1.26%，平均加样回收率为98.54%。
结论：高效液相色谱法测定健胃消食片中橙皮苷含量不仅对加强中药质量控制方面起重要作用，而且对药品中其他成分的含量测定有了深刻的启发。
【关键词】高效液相色谱法；橙皮苷；健胃消食片【中图分类号】R286.0 【文献标识码】A 【文章编号】2095-1752（2017）33-0042-02Determination of Hesperidin in Jianwei Xiaoshi Tablets by High Performance Liquid ChromatographyYu Jie.Suining City Maternal and Child Health Care Family Planning Service Center Pharmacy,Suining 629000,China【Abstract】Objective To determine the content of hesperidin in Jianwei Xiaoshi Tablets by high performance liquid chromatography (HPLC). Methods The chromatographic column: VP-ODS column (4.6mm * 250mm, 5um), column temperature 30℃, mobile phase: methanol: 0.5% glacial acetic acid solution (40:60), detection wavelength: 285nm, Flow rate 1.0ml / min, injection volume 20ul. Results When the injection volume was 0.05 ～12 μg, the injection volume had a good linear relationship with the peak area. RSD = 1.26% and the average recovery was 98.54% when the instrument had good precision. Conclusion The determination of hesperidinin Jianwei Xiaoshi tablet by high performance liquid chromatography is not only an important role in strengthening the quality control of traditional Chinese medicine, but also has a profound inspiration for the determination of other components in medicine.【Key words】HPLC; Hesperidin; Jianwei Xiaoshi tablet健胃消食片是由山楂、陈皮、麦芽、太子参、山药组成的中成药，可采用高效液相色谱法（HPLC法）测定健胃消食片中黄岑苷含量和橙皮苷含量[1]。
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
HPLC法检测蝉拟青霉中N6-(2-羟乙基)-腺苷含量
HPLC法检测蝉拟青霉中N6-(2-羟乙基)-腺苷含量李慧雯;艾仁丽;谭艾娟【期刊名称】《湖北农业科学》【年(卷),期】2022(61)19【摘要】为了建立蝉拟青霉(Paecilomyces cicadae)5704s中N6-(2-羟乙基)-腺苷(HEA)含量测定方法,以去离子水为溶剂,采用超声辅助水浴法提取HEA,基于HPLC法测定其含量。
经优化确定色谱条件为Agilent ZORBAX Extend-C色谱柱(250 mm×4.6 mm,5μm),流动相为甲醇∶5 mmol/L乙酸铵(含0.1%甲酸),梯度洗脱,检测波长为260 nm,流速为1.0 mL/min,柱温为25℃,进样量为10μL。
结果显示,HEA浓度为0.25~100.00μg/mL时,峰面积和HEA含量之间线性关系良好,R^(2)=0.9999,仪器的检出限为0.25μg/mL,平均回收率为97.73%~108.95%,RSD为0.37%~1.29%,测得样品中HEA含量为0.78 mg/g。
该方法简便、快捷、准确、稳定,适用于蝉拟青霉5704s菌丝体中HEA的测定。
【总页数】5页(P114-118)【作者】李慧雯;艾仁丽;谭艾娟【作者单位】贵阳市农业农村局乡村振兴服务中心品牌建设服务站;贵州大学生命科学学院【正文语种】中文【中图分类】R284.2【相关文献】1.HPLC法检测HDBRS-1菌株发酵液中2-羟基联苯含量2.GC法检测头孢噻肟钠中2-乙基己酸含量3.RP-HPLC法测定蝉拟青霉中腺苷的含量4.HPLC-UV法测定蝙蝠蛾拟青霉菌粉中腺苷的含量5.含朱砂中成药中甲基汞和乙基汞含量的HPLC-ICP-MS法检测因版权原因，仅展示原文概要，查看原文内容请购买。
高效液相色谱法测定西米替丁血药浓度
高效液相色谱法测定西米替丁血药浓度
潘炳慧;李煜东
【期刊名称】《安徽医科大学学报》
【年(卷),期】2000(35)5
【摘要】@@ 西米替丁(甲氰咪胍,CMTD)是H2受体阻断剂,主要用于治疗胃及十二指肠溃疡等疾病,但该药偶可致较严重的毒副反应[1～3].根据临床需要,我们利用高效液相色谱法开发了西米替丁血药浓度的测定方法,方法简便、结果准确,现报道如下.
【总页数】2页(P403-404)
【作者】潘炳慧;李煜东
【作者单位】安徽省安庆市立医院药剂科,安庆,246003;安徽省安庆市立医院药剂科,安庆,246003
【正文语种】中文
【中图分类】R446.1;R975.6
【相关文献】
1.高效液相色谱法测定复方西米替丁胶囊中西米替丁的含量 [J], 李晨辉;林惠菁
2.反相高效液相色谱法测定人血浆中西米替丁浓度 [J], 陈季凤;程锦坤
3.超高效液相色谱法测定人血清中伏立康唑血药浓度与临床应用 [J], 陈君;黄春新;王敏
4.超高效液相色谱-串联质谱法测定血浆中伏立康唑的浓度及其在深部真菌感染患
者伏立康唑血药浓度监测中的应用 [J], 葛欣;刘妍妍;刘平
5.高效液相色谱法测定人血清中替考拉宁的血药浓度及其应用 [J], 王石健;夏修远因版权原因，仅展示原文概要，查看原文内容请购买。
荧光分光光度法测定氟康唑胶囊和注射液的含量
荧光分光光度法测定氟康唑胶囊和注射液的含量
李咏梅
【期刊名称】《广东药学院学报》
【年(卷),期】2001(017)001
【摘要】目的：用荧光分光光度法直接测定氟康唑胶囊剂及注射液的含量。
方法：以水作为溶剂。
261nm为激发波长，285nm为发射波长，狭缝为10nm，灵敏
度为中。
结果：氟康唑在1.0～40.0μg/mL浓度范围内与荧光强度呈线性关系，
氟康唑胶囊剂及注射液平均回收率分别为99.6%和100.2%，RSD分别为1.21%
和0.70%。
结论：本法可用于氟康唑胶囊和注射液含量的测定。
【总页数】2页(P49-50)
【作者】李咏梅
【作者单位】广州港港湾医院药剂科，广东广州 510700
【正文语种】中文
【中图分类】R927.2
【相关文献】
1.荧光分光光度法测定甲磺酸培氟沙星注射液的含量 [J], 邱颖姮
2.荧光分光光度法测定洛美沙星注射液及胶囊的含量 [J], 张若燕;欧阳晓玫
3.荧光分光光度法测定盐酸多沙普仑注射液的含量 [J], 王海花;邱颖姮;李玉兰
4.荧光分光光度法测定硫酸沙丁胺醇注射液的含量 [J], 徐影;邱颖姮
5.用荧光分光光度法测定潘生丁注射液中潘生丁的含量 [J], 孙国祥;林秋婕;夏维杰
因版权原因，仅展示原文概要，查看原文内容请购买。
用于结核分枝杆菌耐药性检测的国产体外诊断试剂首次获批
用于结核分枝杆菌耐药性检测的国产体外诊断试剂首次获批本刊讯
【期刊名称】《中国医院用药评价与分析》
【年(卷),期】2016(0)9
【摘要】本刊讯2016年9月2日,国家食品药品监督管理总局经审查,批准了厦门致善生物科技有限公司生产的＂结核分枝杆菌氟喹诺酮类药物耐药突变检测试剂盒（荧光PCR熔解曲线法）＂＂结核分枝杆菌链霉素耐药突变检测试剂盒（荧光PCR熔解曲线法）＂和＂结核分枝杆菌乙胺丁醇耐药突变检测试剂盒（荧光PCR 熔解曲线法）＂。
3个产品都由扩增试剂、对照试剂和提取试剂组成。
【总页数】1页(P1293-1293)
【关键词】耐药突变;耐药性检测;体外诊断试剂;试剂盒;熔解曲线;药品监督;药物耐药性;氟喹诺酮类药物;用械安全;耐多药结核病
【作者】本刊讯
【作者单位】
【正文语种】中文
【中图分类】R951
【相关文献】
1.基因芯片法用于检测长沙地区结核分枝杆菌耐药性研究 [J], 邓叶华;向延根;马小华;石国民;喻容;彭雪峰
2.DNA 微阵列芯片法用于检测结核分枝杆菌耐药性的研究 [J], 刘亚芹;杨振斌;冯
冬霞;王海英
3.高分辨率熔解曲线技术用于结核分枝杆菌临床分离株异烟肼耐药性的快速检测[J], 杨彩虹;杨敏;于璐;包海洋;吴长新;曹旭东;陈创夫
4.国产耐药结核菌体外诊断试剂获批 [J],
5.利用植物生产可用于检测人血中艾滋病毒的体外诊断试剂 [J],
因版权原因，仅展示原文概要，查看原文内容请购买。
PHA-793887_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:PHA–793887 is a novel pan–cdk inhibitor, including cdk1, cdk2, cdk4, cdk5, cdk7, and cdk9 with IC50 in the 5 to 140 nM range.IC50 Value: 8 nM (CDK2), 5 nM(CDK5), 10 nM (CDK7)Target: CDKsin vitro: PHA–793887 is cytotoxic for leukemic cell lines, including K562, KU812, KCL22, and TOM1, with IC50 of 0.3–7 μM, but it is not cytotoxic for normal unstimulated peripheral blood mononuclear cells or CD34+ hematopoietic stem cells. In colony assays,PHA–793887 shows very high activity against leukemia cell lines with IC50 less than 0.1 μM. PHA–793887 induces cell–cycle arrest,inhibits Rb and nucleophosmin phosphorylation, and modulates cyclin E and cdc6 expression at 0.2–1 μM and induces apoptosis at 5μM. PHA–793887 has low activity against CDK1, CDK4, CDK9 and GSK3β with IC50 of 60 nM, 62 nM, 138 nM and 79 nM, respectively.PHA–793887 inhibits cell proliferation of many tumor cell lines, including A2780, HCT–116, COLO–205, C–433, DU–145, A375, PC3,MCF–7, and BX–PC3, with IC50 of 88 nM–3.4 μM. PHA–793887 (1 μM) shows a decrease in the S phase, a subsequent increase of the G1 phase and a slight accumulation of G2/M phase in A2780 cells. PHA–793887 (3 μM) significantly increases G2/M phase and reduces DNA synthsis.in vivo: PHA–793887 (20 mg/kg) is effective in xenograft models of K562 and HL60 cells, primary leukemic disseminated model, and a high–burden disseminated ALL–2 model derived from a relapsed Philadelphia–positive acute lymphoid leukemia patient. PHA–793887(10–30 mg/kg) shows good efficacy in the human ovarian A2780, colon HCT–116, and pancreatic BX–PC3 carcinoma xenograft models.PROTOCOL (Extracted from published papers and Only for reference)Animal administration [1]A2780 human ovarian adenocarcinoma–bearing CD–1 nude mice (Charles River Breeding Laboratories) were treated with 15 or 30mg/kg of PHA–793887 once a day by i.v. route for 2 days. Animals were sacrificed at 1.5, 6, and 24 hours after the last treatment, and tumor slices from mice treated with compound or vehicle (n = 9 animals per group) were collected and immediately soaked inRNAlater solution (Qiagen) for gene expression analysis. For pharmacokinetic analysis, plasma samples were collected from six animals at each time interval and analyzed by liquid chromatography–tandem mass spectrometry. Data were evaluated by nonlinear mixed effect modeling. Plasma levels of the compound were fitted using a two–compartment model with bolus input and first–order output mean, and random parameters were considered in the following equation: Pi = P.exp (η). The random effects were considered normal distributed with zero mean and variance ω2.References:[1]. Locatelli G et al Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin–dependent kinase inhibitor PHA–793887 inProduct Name:PHA–793887Cat. No.:HY-11001CAS No.:718630-59-2Molecular Formula:C 19H 31N 5O 2Molecular Weight:361.48Target:CDK Pathway:Cell Cycle/DNA Damage Solubility:10 mM in DMSOtumor and skin biopsies from a phase I clinical study. Mol Cancer Ther. 2010 May;9(5):1265–73.[2]. Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, Laffranchi B, Pellizzoni C, Kroemer G, Armand JP, Balheda R, Twelves CJ.A first in man, phase I dose–escalation study of PHA–793887, an inhibitor of multiple cyclin–dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.Cell Cycle. 2011 Mar 15;10(6):963–70. Epub 2011 Mar 15.[3]. Alzani R, Pedrini O, Albanese C, Ceruti R, Casolaro A, Patton V, Colotta F, Rambaldi A, Introna M, Pesenti E, Ciomei M, Golay J.Therapeutic efficacy of the pan–cdk inhibitor PHA–793887 in vitro and in vivo in engraftment and high–burden leukemia models.Exp Hematol. 2010 Apr;38(4):259–269.e2. Epub 2010 Feb 16.[4]. Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M, Volpi D, Vulpetti A, Ciomei M.Optimization of 6,6–dimethyl pyrrolo[3,4–c]pyrazoles: Identification of PHA–793887, a potent CDK inhibitor suitable for intravenous dosing.Bioorg Med Chem. 2010 Mar 1;18(5):1844–53. Epub 2010 Jan 25.[5]. Zoubir M, Flament C, Gdoura A, Bahleda R, Litvinova E, Soumelis V, Conforti R, Viaud S, Soria JC, Kroemer G, Zitvogel L, Chaput N.An inhibitor of cyclin–dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.Cell Cycle. 2011 Jan 1;10(1):118–26. Epub 2011 Jan 1.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。